Literature DB >> 30684047

Managing malignant pleural mesothelioma: experience and perceptions of health care professionals caring for people with mesothelioma.

Anne Warby1,2, Haryana M Dhillon1, Steven Kao2,3,4, Janette L Vardy5,6,7,8.   

Abstract

BACKGROUND: Malignant pleural mesothelioma (MPM) has a poor prognosis and heavy symptom burden. Here, we investigate health professionals' attitudes to management and decision-making in people with MPM.
METHODS: Survey questions were based on previous interviews with health professionals, MPM patients, and caregivers. Surveys were sent to specialist doctors and nurses who treat MPM.
RESULTS: Surveys were completed by 107 doctors and 19 nurses from January-September 2014. Most doctors were respiratory physicians (50%) or medical oncologists (35%). Overall, 90% of doctors estimated > 10% of eligible MPM patients did not receive chemotherapy; 43% estimated the rate was > 20%. Doctors believed clinical barriers to chemotherapy were clinician nihilism (70%); non-referral to medical oncology (49%); and lack of specialists in rural/regional areas (44%). Nurses perceived barriers as follows: delayed diagnosis (74%); non-referral to medical oncology (63%); lack of clinician knowledge (58%). Patient-related barriers were negative perception of chemotherapy (83%) and belief survival benefit not worthwhile (63%). Doctors' preference in decision-making was for the patient to make the decision while strongly considering the doctor's opinion (33%); equally with the doctor (29%); and using knowledge gained (23%). Nurses described their roles as providing patient support (100%); information (95%); intermediary (74%); and link to palliative care (74%). Overall, 95% believed they enabled better resource allocation and provided patients with holistic care (95%); clearer communication (89%); more time (89%); additional information (89%); timely referrals (89%).
CONCLUSIONS: Caring for patients with MPM is challenging and complex. Health care professionals believe under-utilisation of chemotherapy is occurring, primarily due to clinician nihilism and lack of medical oncology referral.

Entities:  

Keywords:  Chemotherapy; Decision-making; Health care professionals; Malignant pleural mesothelioma

Mesh:

Year:  2019        PMID: 30684047     DOI: 10.1007/s00520-019-4648-0

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  20 in total

Review 1.  The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.

Authors:  Peter Ellis; Angela M Davies; William K Evans; Adam E Haynes; Nancy S Lloyd
Journal:  J Thorac Oncol       Date:  2006-07       Impact factor: 15.609

2.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

Review 3.  Patients' preferences for chemotherapy in non-small-cell lung cancer: a systematic review.

Authors:  Prunella Blinman; Mahmood Alam; Vlatka Duric; Sue-Anne McLachlan; Martin R Stockler
Journal:  Lung Cancer       Date:  2010-05-31       Impact factor: 5.705

4.  Physicians' evaluations of patients' decisions to refuse oncological treatment.

Authors:  T van Kleffens; E van Leeuwen
Journal:  J Med Ethics       Date:  2005-03       Impact factor: 2.903

5.  Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.

Authors:  Jan P van Meerbeeck; Rabab Gaafar; Christian Manegold; Rob J Van Klaveren; Eric A Van Marck; Mark Vincent; Catherine Legrand; Andrew Bottomley; Channa Debruyne; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

6.  A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.

Authors:  M E R O'Brien; D Watkins; C Ryan; K Priest; C Corbishley; A Norton; S Ashley; N Rowell; R Sayer
Journal:  Ann Oncol       Date:  2005-11-29       Impact factor: 32.976

7.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Authors:  Nicholas J Vogelzang; James J Rusthoven; James Symanowski; Claude Denham; E Kaukel; Pierre Ruffie; Ulrich Gatzemeier; Michael Boyer; Salih Emri; Christian Manegold; Clet Niyikiza; Paolo Paoletti
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

8.  Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module.

Authors:  Anna K Nowak; Martin R Stockler; Michael J Byrne
Journal:  J Clin Oncol       Date:  2004-08-01       Impact factor: 44.544

9.  An evaluation of the impact of a multidisciplinary team, in a single centre, on treatment and survival in patients with inoperable non-small-cell lung cancer.

Authors:  L M Forrest; D C McMillan; C S McArdle; D J Dunlop
Journal:  Br J Cancer       Date:  2005-10-31       Impact factor: 7.640

10.  Declining conventional cancer treatment and using complementary and alternative medicine: a problem or a challenge?

Authors:  M J Verhoef; M S Rose; M White; L G Balneaves
Journal:  Curr Oncol       Date:  2008-08       Impact factor: 3.677

View more
  7 in total

1.  Living beyond expectations: a qualitative study into the experience of long-term survivors with pleural mesothelioma and their carers.

Authors:  Matthew Johnson; Peter Allmark; Angela Tod
Journal:  BMJ Open Respir Res       Date:  2022-05

2.  Understanding the palliative care needs and experiences of people with mesothelioma and their family carers: An integrative systematic review.

Authors:  Madeleine Harrison; Clare Gardiner; Bethany Taylor; Stephanie Ejegi-Memeh; Liz Darlison
Journal:  Palliat Med       Date:  2021-04-08       Impact factor: 4.762

3.  A review of malignant pleural mesothelioma in a large North East UK pleural centre.

Authors:  Declan C Murphy; Alexander Mount; Fiona Starkie; Leah Taylor; Avinash Aujayeb
Journal:  Pleura Peritoneum       Date:  2020-12-09

4.  Improving mesothelioma follow-up care in the UK: a qualitative study to build a multidisciplinary pyramid of care approach.

Authors:  Zoe Davey; Catherine Henshall
Journal:  BMJ Open       Date:  2021-11-10       Impact factor: 2.692

5.  Improving outcomes in malignant pleural mesothelioma in an integrated health care system.

Authors:  Stephanie Ossowski; Yun-Yi Hung; Kian Banks; Diana Hsu; Lisa Herrinton; Simon Ashiku; Ashish Patel; J Marie Suga; Jeffrey B Velotta
Journal:  J Thorac Dis       Date:  2022-09       Impact factor: 3.005

Review 6.  A narrative review of the health disparities associated with malignant pleural mesothelioma.

Authors:  Devon C Freudenberger; Rachit D Shah
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

7.  Malignant pleural mesothelioma patients' experience by gender: findings from a cross-sectional UK-national questionnaire.

Authors:  Michaela Senek; Steve Robertson; Liz Darlison; Lorraine Creech; Angela Tod
Journal:  BMJ Open Respir Res       Date:  2022-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.